Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Up 62.7% in March

Hoth Therapeutics, Inc. (NASDAQ:HOTH) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 283,200 shares, a growth of 62.7% from the February 28th total of 174,100 shares. Currently, 2.2% of the company’s shares are sold short. Based on an average daily volume of 8,500,000 shares, the short-interest ratio is presently 0.0 days.

Institutional Investors Weigh In On Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC bought a new position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.47% of Hoth Therapeutics as of its most recent filing with the SEC. 7.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on HOTH shares. HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Hoth Therapeutics in a research report on Thursday, January 23rd. D. Boral Capital reiterated a “buy” rating and issued a $5.00 price target on shares of Hoth Therapeutics in a report on Monday.

Hoth Therapeutics Stock Down 1.9 %

Shares of HOTH traded down $0.02 during mid-day trading on Monday, hitting $1.01. The company had a trading volume of 151,201 shares, compared to its average volume of 3,413,166. Hoth Therapeutics has a 1-year low of $0.58 and a 1-year high of $3.80. The business’s 50-day simple moving average is $1.13 and its 200-day simple moving average is $1.01. The stock has a market cap of $6.97 million, a PE ratio of -0.77 and a beta of 0.84.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. On average, sell-side analysts expect that Hoth Therapeutics will post -1.36 earnings per share for the current year.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.